

Anti-SMAD3 (pT179) Antibody

Rabbit polyclonal antibody to SMAD3 (pT179)

Catalog # AP60397

Product Information

Application	WB, IHC
Primary Accession	P84022
Other Accession	Q8BUN5
Reactivity	Human, Mouse, Rat, Monkey, Pig, Dog, SARS
Host	Rabbit
Clonality	Polyclonal
Calculated MW	48081

Additional Information

Gene ID	4088
Other Names	MADH3; Mothers against decapentaplegic homolog 3; MAD homolog 3; Mad3; Mothers against DPP homolog 3; hMAD-3; JV15-2; SMAD family member 3; SMAD 3; Smad3; hSMAD3
Target/Specificity	KLH-conjugated synthetic peptide encompassing a sequence within the center region of human SMAD3 (pT179). The exact sequence is proprietary.
Dilution	WB~~WB (1/500 - 1/1000), IHC (1/100 - 1/200) IHC~~WB (1/500 - 1/1000), IHC (1/100 - 1/200)
Format	Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.09% (W/V) sodium azide.
Storage	Store at -20 °C.Stable for 12 months from date of receipt

Protein Information

Name	SMAD3
Synonyms	MADH3
Function	Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP- 1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on

wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.


Cellular Location

Cytoplasm. Nucleus. Note=Cytoplasmic and nuclear in the absence of TGF-beta. On TGF-beta stimulation, migrates to the nucleus when complexed with SMAD4 (PubMed:15799969, PubMed:21145499). Through the action of the phosphatase PPM1A, released from the SMAD2/SMAD4 complex, and exported out of the nucleus by interaction with RANBP1 (PubMed:16751101, PubMed:19289081). Co-localizes with LEMD3 at the nucleus inner membrane (PubMed:15601644). MAPK-mediated phosphorylation appears to have no effect on nuclear import (PubMed:19218245). PDPK1 prevents its nuclear translocation in response to TGF-beta (PubMed:17327236). Localized mainly to the nucleus in the early stages of embryo development with expression becoming evident in the cytoplasm of the inner cell mass at the blastocyst stage (By similarity) {ECO:0000250|UniProtKB:Q8BUN5, ECO:0000269|PubMed:15601644, ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:21145499}


Background

KLH-conjugated synthetic peptide encompassing a sequence within the center region of human SMAD3 (pT179). The exact sequence is proprietary.

Images



Western blot analysis of SMAD3 (pT179) expression in Hela (A), A549 (B) whole cell lysates.



Immunohistochemical analysis of SMAD3 (pT179) staining in human brain formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.